Book contents
- Androgens in Gynecological Practice
- Androgens in Gynecological Practice
- Copyright page
- Contents
- About the editors
- Dedication
- Contributors
- Preface
- Section 1 Managing the basics
- 1 Hirsutism: managing the basics
- 2 Alopecia: managing the basics
- 3 Polycystic ovary syndrome: managing the basics
- 4 Sexual dysfunction, including hypoactive sexual desire disorder: Diagnosis and treatment recommendations
- Section 2 The scientific essentials
- Section 3 Learning from the extremes
- Section 4 The tool kit
- Index
- Plate Section
- References
3 - Polycystic ovary syndrome: managing the basics
from Section 1 - Managing the basics
Published online by Cambridge University Press: 05 July 2015
Book contents
- Androgens in Gynecological Practice
- Androgens in Gynecological Practice
- Copyright page
- Contents
- About the editors
- Dedication
- Contributors
- Preface
- Section 1 Managing the basics
- 1 Hirsutism: managing the basics
- 2 Alopecia: managing the basics
- 3 Polycystic ovary syndrome: managing the basics
- 4 Sexual dysfunction, including hypoactive sexual desire disorder: Diagnosis and treatment recommendations
- Section 2 The scientific essentials
- Section 3 Learning from the extremes
- Section 4 The tool kit
- Index
- Plate Section
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Androgens in Gynecological Practice , pp. 25 - 37Publisher: Cambridge University PressPrint publication year: 2015
References
1.McDonough, PG. How many of the items in the polycystic ovary syndrome can be validated statistically? Fertil Steril 2006;85:530–1.Google Scholar
2.Azziz, R, Woods, KS, Reyna, R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. JCEM 2004;89:2745–9.CrossRefGoogle Scholar
3.Stein, LF, Leventhal, ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;77:826.Google Scholar
4.National Institutes of Health Evidence-based Methodology Workshop on Polycystic Ovary Syndrome, December 2012; pages 1–14 at http://prevention.nih.gov/workshops/2012/pcos/.Google Scholar
5.Eisner, JR, Barnett, MA, Dumesic, DA, Abbott, DH. Ovarian hyperandrogenism is adult female rhesus monkeys exposed to prenatal androgen excess. Fertil Steril 2002;77:167–72.Google Scholar
6.Franks, S, McCarthy, MI, Hardy, K. Development of polycystic ovary syndrome: involvement of genetic and environmental factors. Int J Androl 2006;29:278–85.Google Scholar
7.De Boo, HA, Harding, JE. The developmental origins of adult disease (Barker) hypothesis. Aust N Z J Obstet Gynaecol 2006;46:4–14.CrossRefGoogle ScholarPubMed
8.The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–7.Google Scholar
9.Kaltsas, GA, Mukherjee, JJ, Jenkins, PJ, et al. Menstrual irregularity in women with acromegaly. J Clin Endocrinol Metab 1999;84:2731–5.Google Scholar
10.Azziz, R, Carmina, E, Dewailly, D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456–88.CrossRefGoogle ScholarPubMed
11.Wiksten-Almstromer, M, Hirschberg, AL, Hagenfeldt, K. Prospective follow-up of menstrual disorders in adolescence and prognostic factors. Acta Obstet Gynecol Scand 2008;87:1162–8.CrossRefGoogle ScholarPubMed
12.Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation 2002;10:3143–421.Google Scholar
13.Ferriman, D, Gallwey, JD. Clinical assessment of body hair growth in women. J Clin Endocrinol 1961;21:1440–7.Google Scholar
14.De Ronde, W. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod 2009;24:425–8.Google Scholar
15.Dhont, M. WHO-classification of anovulation: background, evidence and problems. Gynaecology, Obstetrics, and Reproductive Medicine in Daily Practice: International Congress Series 2005;1279:3–9.Google Scholar
16.Friedman, CI, Schmidt, GE, Kim, MH, et al: Serum testosterone concentrations in the evaluation of androgen-producing tumors. Am J Obstet Gynecol 1985;153:44–9.Google Scholar
17.Derksen, J, Nagesser, SK, Meinders, AE, et al: Identification of virilizing adrenal tumors in hirsute women. N Engl J Med 1994;331:968–73.CrossRefGoogle ScholarPubMed
18.New, MI. Extensive clinical experience: nonclassical 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006;91:4205–14.Google Scholar
19.Papanicolaou, DA, Yanovski, JA, Cutler, GB, et al. A single midnight serum cortisol measurement distinguishes Cushing’s syndrome from Pseudo-Cushing states. J Clin Endocrinol Metab 1998;83:1163–7.Google ScholarPubMed
20.American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly. Endocr Pract 2004;10(3):213–25.Google Scholar
21.Melmed, S. Medical progress: acromegaly. N Engl J Med 2006;355:2558–73.CrossRefGoogle ScholarPubMed
22.Freda, PU, Post, KD, Powell, JS, Wardlaw, SL. Evaluation of disease status with sensitive measures of GH secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 1998;83:3808–16.Google ScholarPubMed
23.Carmina, E, Rosato, F, Jannì, A, et al. Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 2006;91:2–6.Google Scholar
24.Lobo, RA, Carmina, E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000;132:989–93.CrossRefGoogle ScholarPubMed
25.Adams, J, Polson, DW, Franks, S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986;293:355–9.Google Scholar
26.Pigny, P, Merlen, E, Robert, Y, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 2003;88:5957–62.CrossRefGoogle Scholar
27.Jonard, S, Robert, Y, Cortet-Rudelli, C, et al. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003;18:598–603.Google Scholar
28.Jonard, S, Robert, Y, Dewailly, D. Revisiting the ovarian volume as a diagnostic criterion for polycystic ovaries. Hum Reprod 2005;20:2893–8.CrossRefGoogle ScholarPubMed
29.Ehrmann, DA, Barnes, RB, Rosenfield, RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22:141–6.CrossRefGoogle ScholarPubMed
30.Ehrmann, DA. Polycystic ovary syndrome. Medical progress. N Engl J Med 2005;352:1223–36.Google Scholar
31.Genuth, S, Alberti, KG, Bennett, P, et al. Follow-up report on the diagnosis of diabetes mellitus. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003;26:3160–7.Google Scholar
32.Management of abnormal uterine bleeding associated with ovulatory dysfunction. Practice Bulletin No. 136. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013;122:176–85.Google Scholar
33.Haidopoulos, D, Simou, M, Akrivos, N, et al. Risk factors in women 40 years of age and younger with endometrial carcinoma. Acta Obstet Gynecol Scand 2010;89:1326–30.CrossRefGoogle ScholarPubMed
34.Pellerin, GP, Finan, MA. Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis. Am J Obstet Gynecol 2005;193:1640–4.Google Scholar
35.Vgontzas, AN, Legro, RS, Bixler, EO, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001;86:517–20.Google Scholar
36.Fogel, RB, Malhotra, A, Pillar, G, et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:1175–80.Google Scholar
37.Deeks, AA, Gibson-Helm, ME, Teede, HJ. Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation. Fertil Steril 2010;93:2421–3.Google Scholar
38.Beck, AT, Steer, RA, Ball, R, Ranieri, WF. Comparison of Beck Depression Inventories-IA and –II in psychiatric outpatients. J Pers Assess 1996;67:588–97.CrossRefGoogle Scholar
39.Zigmond, A, Snaith, R. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361–70.Google Scholar
40.Huber-Buchholz, MM, Carey, DG, Norma, RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470–4.Google Scholar
41.Nestler, JE, Jakubowicz, DJ, Evans, WS, Pasquali, R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876–80.Google Scholar
42.Greenblatt, RB, Barfield, WE, Jungck, EC, Ray, AW. Induction of ovulation with MRL. JAMA 1960;178:101–5.Google Scholar
43.Lunenfeld, B. Treatment of anovulation by human gonadotropins. Int J Obstet Gynecol 1963;1:153–7.Google Scholar
44.Homburg, R. Clomiphene citrate-end of an era? A mini-review. Hum Reprod 2005;20:2043–51.CrossRefGoogle Scholar
45.Tulandi, T, Martin, J, Al-Fadhli, R, et al. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril 2006;85:1761–5.Google Scholar
46.Fauser, BC, van Heusden, AM. Manipulation of human ovarian function: physiological concepts and clinical consequences. Endocr Rev 1997;18:71–106.Google Scholar
47.Gjonnaess, H. Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril 1984;41:20–5.CrossRefGoogle ScholarPubMed
48.Palomba, S, Orio, F, Jr, Nardo, LG, et al. Metformin administration versus laparoscopic ovarian diathermy in clomiphene-resistant women with polycystic ovarian syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab 2004;89:4801–9.Google Scholar
49.Diamanti-Kandarakis, E, Baillargeon, J-P, Iuorno, MJ, et al. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003;88:1927–33.Google Scholar
50.Moghetti, P, Tosi, F, Tosti, A, et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2000;85:89–94.Google ScholarPubMed
51.Venturoli, S, Marescalchi, O, Colombo, FM, et al. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab, 1999;84:1304–10.Google Scholar
52.Orchard, TJ, Temprosa, M, Goldberg, R, et al. Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142:611–19.CrossRefGoogle Scholar
53.Malik, SM, Traub, ML. Defining the role of bariatric surgery in polycystic ovarian syndrome patients. World J Diabetes 2012;3:71–9.CrossRefGoogle ScholarPubMed